Given that the increase in the aging population has grown into one of the largest public
health issues, inflammation and oxidative stress, which are closely associated with the aging …

Large placebo-controlled clinical trials have shown that sodium-glucose cotransporter-2
inhibitors (SGLT2i) delay the deterioration of renal function and reduce cardiovascular …

The immune system is intimately involved in the pathophysiology of heart failure. However, it
is currently underused as a therapeutic target in the clinical setting. Moreover, the …

The global prevalence of diabetes mellitus (DM) has led to widespread multi-system
damage, especially in cardiovascular and renal functions, heightening morbidity and …

Vascular calcification (VC) is associated with increased cardiovascular risks in patients with
chronic kidney disease (CKD). Sodium-glucose cotransporter 2 inhibitors, such as …

Aging is widespread worldwide and a significant risk factor for cardiovascular disease
(CVD). Mechanisms underlying aging have attracted considerable attention in recent years …

Cancer and cardiovascular disorders are known as the two main leading causes of mortality
worldwide. Cardiotoxicity is a critical and common adverse effect of cancer-related …

Background The low-grade chronic inflammation in diabetes plays an important role in
development of cardiovascular and renal complications. Sodium-glucose co-transporter-2 …

Sudden cardiac death (SCD) accounts for a substantial proportion of mortality in heart failure
with reduced ejection fraction (HFrEF), frequently triggered by ventricular arrhythmias (VA) …

Objective To investigate whether empagliflozin could prevent injury-induced vascular
neointimal hyperplasia and to further explore its mechanism. Methods Male C57BL/6J mice …